Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance

Hyung L. Kim; Ping Li; Huei-Chung Huang; Samineh Deheshi; Tara Marti; Beatrice S. Knudsen; Hatem Abou–Ouf; Ridwan Alam; Tamara L. Lotan; Lucia L.C. Lam; Marguerite du Plessis; Elai Davicioni; Neil Fleshner; Brian R. Lane; Ashley E. Ross; John W. Davis; James L. Mohler; Bruce J. Trock; Eric A. Klein; Jeffrey J. Tosoian; M. Eric Hyndman; Tarek A. Bismar

doi:10.1038/s41391-018-0101-6

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Decipher can be applied to prostate biopsies from NCCN-very-low/low and favorable-intermediate risk patients to predict absence of adverse pathologic features. These patients are predicted to be good candidates for active surveillance.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2018) studied this question.

synapsesocial.com/papers/69d7711faa68b335b4f3176c https://doi.org/10.1038/s41391-018-0101-6

View Full Paper

Ask AI

Bookmark

Share

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance

Ask about this paper

Abstract

Discussion

Cite This Study

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading